Previous studies have shown markers of inflammation (such as low serum albumin, interleukin 6 (IL-6), C-reactive protein (CRP), and bone and mineral metabolism (such as hyperphosphatemia, hypercalcemia, increased CaxPO4 product, secondary hyperparathyroidism, high levels of FGF23, and Klotho) independently or in combination predict adverse outcomes [3,4,5,6], significantly those linked to cardiovascular comorbidity and mortality in end-stage renal disease (ESRD) patients [7,8,9,10]. This evidence concerns the gene CRP and hypercalcemia disease.